Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United Kingdom
/
Healthcare
/
Tristel
TSTL
Tristel
US Expansion And Direct Sales Will Open New Opportunities
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
02 May 25
Updated
24 Jul 25
9
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
UK£4.46
14.7% undervalued
intrinsic discount
24 Jul
UK£3.80
Loading
1Y
-18.7%
7D
-0.4%
Author's Valuation
UK£4.5
14.7% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
UK£4.5
14.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
60m
2014
2017
2020
2023
2025
2026
2028
Revenue UK£60.1m
Earnings UK£10.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.53%
Medical Equipment revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.66%
Calculation
UK£10.55m
Earnings '28
x
25.16x
PE Ratio '28
=
UK£265.54m
Market Cap '28
UK£265.54m
Market Cap '28
/
48.16m
No. shares '28
=
UK£5.51
Share Price '28
UK£5.51
Share Price '28
Discounted to 2025 @ 7.48% p.a.
=
UK£4.44
Fair Value '25